| hypoxia-inducible factor 1 negatively regulates mitochondrial biogenesis and O(2) consumption in renal carcinoma cells lacking the von Hippel-Lindau tumor suppressor | kidney, |
| these findings provide that Mel-18 is a novel regulator of tumor angiogenesis through regulating HIF-1alpha and its target VEGF expressions mediated by the PTEN/PI3K/Akt pathway, suggesting a new tumor-suppressive role of Mel-18 in human breast cancer. | breast, |
| HIF-1alpha can act as a tumor suppressor gene in murine acute myeloid leukemia. | leukemia, |
| Factor inhibiting HIF1alpha (FIH-1) functions as a tumor suppressor in human colorectal cancer by repressing HIF1alpha pathway | colorectal, |
| HIF-1alpha is regulated by the von Hippel-Lindau tumor suppressor gene product | None |
| data report a novel von Hippel-Lindau tumor suppressor-interacting protein (VHLaK) that functions as a negative regulator of HIF-1alpha transactivation; findings provide a novel mechanism for the modulation of HIF-1alpha transactivation by pVHL | None |
| pvon Hippel-Lindau tumor suppressor itself is induced in prolonged hypoxia in a kinetic that parallels the observed downregulation of HIF-1alpha protein under such conditions | None |
| Review of overall findings demonstrates the essential role of the hypoxia/von Hippel Lindau tumor suppressor/HIF-1 alpha pathway in endochondral bone development. | None |
| This study demonstrated that HDAIs repress both HIF-1alpha and HIF-2alpha transactivation potential independently of von Hippel-Lindau tumor suppressor and p53 function, and indicates that HDAIs may have biological effects in a broad range of tissues. | None |
| Data show that during placental development, HIF1A is regulated by temporal and spatial changes in expression and association of molecules forming the multi-protein von Hippel-Lindau tumor suppressor complex as well as prolyl hydroxylase activities. | None |
| Results confirm that HIF-2alpha is tumor suppressive, and suggest that HIF-1alpha may also be tumor suppressive. | None |
| These results identify FHL proteins as negative regulators of HIF-1 activity, which may provide a mechanism by which they suppress tumor growth. | None |
| HIF1alpha acts as a tumor promoter in stromal cells but as a tumor suppressor in cancer cells. | None |
| HIF-1 is activated in cancer cells by tumor suppressor loss of function and oncogene gain of function and mediates metabolic alterations that drive cancer progression and resistance to therapy. [Review] | None |
| results indicate that in the M5 sub-type of acute myeloid leukemia, HIF-1alpha plays specific pro-oncogenic functions that are mainly related to promoting leukemia cell motility and dissemination | leukemia, |